

November 23, 2024

Tο

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroze Jeejeebhoy Towers, 25<sup>th</sup> floor, Dalal Street, **MUMBAI -400 001** 

Company Code No. AUROPHARMA

Company Code No. 524804

Dear Sir/Madam.

Sub: Collaboration and License Agreement entered into between a global pharma major and Aurobindo Pharma USA Inc., a wholly owned subsidiary – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a Collaboration and License Agreement on November 22, 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation.

Additional disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure.** 

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Encl.: Annexure

(CIN: L24239TG1986PLC015190)

**AUROBINDO PHARMA LIMITED** 

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.



## **Annexure**

Annexure	
i) name(s) of parties with whom the agreement is signed	A global pharma major
ii) area of agreement	Collaboration and License Agreement (the "Agreement")
iii) domestic/international	International
iv) scope of business operation of agreement	Product Development and Commercialization
v) details of consideration paid in agreement	<ul> <li>An upfront payment of USD 25 million, on the effective date of the agreement.</li> <li>Post the effective date, the developmental costs will be borne by both the parties equally with an overall cap of US\$90 mn for Aurobindo.</li> </ul>
vi) significant terms and conditions of agreement JV in brief	<ul> <li>Collaboration and License Agreement with a global pharma major ("Partner") over an initial estimated development duration of three- five years.</li> <li>Both the parties will collaborate with respect to the development of specific products across respiratory therapeutic area.</li> <li>Both the parties will co-exclusively commercialize the product.</li> <li>The products, once commercialized, will be manufactured at Partner's facility and will be marketed by both the parties. Aurobindo has an option to technology transfer at a future date.</li> <li>The terms of the Agreement remain confidential.</li> </ul>
vii) size of the entity(ies)	Due to confidentiality agreement signed with the Partner, the Company is not permitted disclose the name and other details of the Agreement.
viii) rationale and benefit expected	<ul> <li>Sharing the risks associated with product development</li> <li>Sharing the cost of development</li> <li>Reduce the gestational period for developing the product from scratch</li> <li>To strengthen/diversify our existing product portfolio.</li> </ul>
ix) shareholding, if any, in the entity with whom the agreement is executed	Nil
x) significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	<ul> <li>A cost-sharing arrangement has been agreed by both the parties with each of them contributing 50% of the cost incurred with an overall cap of \$90 mn for Aurobindo over the development period.</li> <li>Partner to have global manufacturing rights for the codeveloped and commercialized products.</li> <li>Aurobindo has an option to technology transfer at a future date.</li> <li>Both the parties will co-exclusively commercialize the product.</li> </ul>

## **AUROBINDO PHARMA LIMITED**

(CIN: L24239TG1986PLC015190) www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.



xi) whether the said parties are related to promoter/promoter group/ Group companies in any manner. If yes, nature of relationship;	No
xii) whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No
xiii) in case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
xiv) in case of loan agreements, details of lender, nature of the loan, total amount of loan granted, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders for such loan;	Not Applicable

## **AUROBINDO PHARMA LIMITED**

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.